Colon cancer screening pill developer Check-Cap sets IPO terms

Check-Cap has become the latest firm to target an initial public offering: it plans to sell 1.2 million shares at $10-12 each, giving it around $13m at the midpoint. If successful, it will trade on the Nasdaq under the ticker symbol CHEK.